Valeant Pharmaceuticals Completes Acquisition of PreCision Dermatology
07/08/2014
Valeant Pharmaceuticals International, Inc. has
completed the previously announced acquisition of PreCision Dermatology,
Inc. PreCision develops and markets high quality dermatology products
with leading products such as Locoid, Hylatopic, and Clindagel.
It had been announced in February that Valeant Pharmaceuticals International, Inc. had entered into a definitive agreement to acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone.